NASDAQ:ARVN Arvinas - ARVN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $27.32 +0.51 (+1.90%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$26.51▼$27.7950-Day Range$26.15▼$37.2652-Week Range$25.35▼$75.39Volume554,494 shsAverage Volume443,511 shsMarket Capitalization$1.46 billionP/E RatioN/ADividend YieldN/APrice Target$68.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Arvinas MarketRank™ ForecastAnalyst RatingModerate Buy2.72 Rating ScoreUpside/Downside151.6% Upside$68.75 Price TargetShort InterestBearish11.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$256,143 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($6.01) to ($7.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector616th out of 1,004 stocksPharmaceutical Preparations Industry301st out of 489 stocks 4.4 Analyst's Opinion Consensus RatingArvinas has received a consensus rating of Buy. The company's average rating score is 2.72, and is based on 13 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $68.75, Arvinas has a forecasted upside of 151.6% from its current price of $27.32.Amount of Analyst CoverageArvinas has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.16% of the float of Arvinas has been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in Arvinas has recently increased by 0.59%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldArvinas does not currently pay a dividend.Dividend GrowthArvinas does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARVN. Previous Next 2.3 News and Social Media Coverage News SentimentArvinas has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.Search Interest3 people have searched for ARVN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows4 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $256,143.00 in company stock.Percentage Held by InsidersOnly 2.78% of the stock of Arvinas is held by insiders.Percentage Held by Institutions92.03% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arvinas are expected to decrease in the coming year, from ($6.01) to ($7.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arvinas is -5.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arvinas is -5.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArvinas has a P/B Ratio of 2.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arvinas (NASDAQ:ARVN) StockArvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.Read More Receive ARVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter. Email Address ARVN Stock News HeadlinesMarch 23, 2023 | americanbankingnews.comAnalysts Set Arvinas, Inc. (NASDAQ:ARVN) PT at $68.44March 21, 2023 | americanbankingnews.comArvinas (NASDAQ:ARVN) Given New $77.00 Price Target at CitigroupApril 1, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.February 24, 2023 | finance.yahoo.comArvinas Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsFebruary 24, 2023 | finance.yahoo.comA Look At The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)February 6, 2023 | finance.yahoo.comArvinas to Participate in Upcoming Investor ConferencesJanuary 11, 2023 | finance.yahoo.comArvinas, Inc. (ARVN) Soars 10.3%: Is Further Upside Left in the Stock?January 4, 2023 | finance.yahoo.comArvinas to Present at 41st Annual J.P. Morgan Healthcare ConferenceApril 1, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.January 3, 2023 | finance.yahoo.comInvestors in Arvinas (NASDAQ:ARVN) from a year ago are still down 57%, even after 5.4% gain this past weekDecember 31, 2022 | finance.yahoo.comArvinas, Inc. (ARVN) Stock Historical Prices & Data - Yahoo FinanceNovember 22, 2022 | finance.yahoo.comArvinas's ARV-471 Achieves Clinical Benefit Rate Of 38% In Breast Cancer SettingNovember 10, 2022 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)November 1, 2022 | finance.yahoo.comArvinas to Present at Upcoming ConferencesNovember 1, 2022 | finance.yahoo.comWhy Arvinas (ARVN) Might Surprise This Earnings SeasonOctober 10, 2022 | reuters.comARVN.N - Arvinas Inc | Stock Price & Latest News | ReutersOctober 4, 2022 | businesswire.comSecretome Therapeutics Announces Appointment of Angela Shen, M.D., M.B.A., to Board of Directors - Business WireOctober 3, 2022 | finance.yahoo.comArvinas Appoints Paul McInulty as Senior Vice President, Regulatory AffairsSeptember 30, 2022 | globenewswire.comArvinas Gives Back to Local Greater New Haven Community - GlobeNewswireSeptember 30, 2022 | finance.yahoo.comArvinas Gives Back to Local Greater New Haven CommunitySeptember 26, 2022 | globenewswire.comArvinas to Present at Bank of America Securities Precision Oncology Conference - GlobeNewswireSeptember 26, 2022 | finance.yahoo.comArvinas to Present at Bank of America Securities Precision Oncology ConferenceSeptember 14, 2022 | streetinsider.comPardes Biosciences (PRDS) Appoints Laurie Smaldone Alsup and John C. Pottage to its Board - StreetInsider.comSeptember 13, 2022 | benzinga.comArvinas (NASDAQ:ARVN) – hC Bioscience Appoints Brad Margus to its Board of Directors - BenzingaSeptember 9, 2022 | benzinga.comArvinas (NASDAQ:ARVN) – Where Arvinas Stands With Analysts - BenzingaSeptember 9, 2022 | seekingalpha.comARVN stock initiated Overweight at Barclays on therapeutic platform (NASDAQ:ARVN) - Seeking AlphaSeptember 9, 2022 | benzinga.comArvinas (NASDAQ:ARVN) – Expert Ratings for Arvinas - BenzingaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ARVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter. Email Address ARVN Company Calendar Last Earnings2/23/2023Today4/01/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARVN CUSIPN/A CIK1655759 Webwww.arvinas.com Phone(203) 535-1456FaxN/AEmployees280Year FoundedN/APrice Target and Rating Average Stock Price Forecast$68.75 High Stock Price Forecast$95.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+151.6%Consensus RatingModerate Buy Rating Score (0-4)2.72 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)($5.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-282,500,000.00 Net Margins-228.19% Pretax Margin-191.02% Return on Equity-43.79% Return on Assets-20.55% Debt Debt-to-Equity RatioN/A Current Ratio4.20 Quick Ratio4.20 Sales & Book Value Annual Sales$131.40 million Price / Sales11.08 Cash FlowN/A Price / Cash FlowN/A Book Value$10.61 per share Price / Book2.57Miscellaneous Outstanding Shares53,270,000Free Float51,790,000Market Cap$1.46 billion OptionableNot Optionable Beta1.78 Key ExecutivesJohn G. HoustonPresident, Chief Executive Officer & DirectorLisa SinclairSenior Vice President-Corporate OperationsSean A. CassidyChief Financial OfficerIan TaylorChief Scientific OfficerRonald PeckChief Medical OfficerKey CompetitorsCureVacNASDAQ:CVACMorphicNASDAQ:MORFSyndax PharmaceuticalsNASDAQ:SNDXVerona PharmaNASDAQ:VRNAAvidity BiosciencesNASDAQ:RNAView All CompetitorsInsiders & InstitutionsJohn G HoustonSold 5,878 sharesTotal: $173,577.34 ($29.53/share)Sean A CassidySold 1,745 sharesTotal: $51,529.85 ($29.53/share)Ian TaylorSold 1,051 sharesTotal: $31,036.03 ($29.53/share)Voya Investment Management LLCSold 24,459 shares on 2/28/2023Ownership: 0.158%NatixisBought 1,592 shares on 2/24/2023Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions ARVN Stock - Frequently Asked Questions Should I buy or sell Arvinas stock right now? 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 5 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARVN shares. View ARVN analyst ratings or view top-rated stocks. What is Arvinas' stock price forecast for 2023? 18 analysts have issued 1 year target prices for Arvinas' shares. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they predict the company's stock price to reach $68.75 in the next year. This suggests a possible upside of 151.6% from the stock's current price. View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts. How have ARVN shares performed in 2023? Arvinas' stock was trading at $34.21 at the beginning of the year. Since then, ARVN stock has decreased by 20.1% and is now trading at $27.32. View the best growth stocks for 2023 here. When is Arvinas' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our ARVN earnings forecast. How were Arvinas' earnings last quarter? Arvinas, Inc. (NASDAQ:ARVN) released its quarterly earnings data on Thursday, February, 23rd. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.10) by $0.46. The firm earned $38 million during the quarter, compared to analysts' expectations of $35.32 million. Arvinas had a negative trailing twelve-month return on equity of 43.79% and a negative net margin of 228.19%. The company's quarterly revenue was up 32.4% on a year-over-year basis. During the same period last year, the company posted ($1.00) EPS. What ETFs hold Arvinas' stock? ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC), BlackRock Future Health ETF (BMED) and Harbor Disruptive Innovation ETF (INNO). What other stocks do shareholders of Arvinas own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD). When did Arvinas IPO? (ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO. What is Arvinas' stock symbol? Arvinas trades on the NASDAQ under the ticker symbol "ARVN." How do I buy shares of Arvinas? Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arvinas' stock price today? One share of ARVN stock can currently be purchased for approximately $27.32. How much money does Arvinas make? Arvinas (NASDAQ:ARVN) has a market capitalization of $1.46 billion and generates $131.40 million in revenue each year. The company earns $-282,500,000.00 in net income (profit) each year or ($5.32) on an earnings per share basis. How many employees does Arvinas have? The company employs 280 workers across the globe. How can I contact Arvinas? Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com. This page (NASDAQ:ARVN) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.